Table 4 Comparison of baseline FT3, FT4, FT3/FT4 ratio and TSH in patients with and without symptoms of neuropsychiatric dysfunction in survivors

Age (year)

59.2 ± 11.4

65.4 ± 8.9^**

62.7 ± 9.8

M/F (%)

54/58 (48.2/51.8)

14/18(43.8/56.2)

16/12(57.1/42.9)

FT3 (pmol/L)

2.89 (2.28, 3.53)

(n = 111)

2.51 ± 0.75^*

(n = 31)

2.78 (2.28, 3.58)

(n = 28)

Prevalence of low serum FT3 (%)

42/111(37.4)

16/31(51.3)

11/28(39.3)

FT4 (pmol/L)

11.8 ± 2.6

(n = 61)

11.2 ± 2.3

(n = 20)

10.36 (9.73, 13.01)

(n = 18)

FT3/FT4 ratio

0.25 ± 0.07

(n = 61)

0.23 ± 0.07

(n = 20)

0.27 ± 0.05^#

(n = 18)

TSH (uIU/mL)

1.49 (1.00, 2.13)

(n = 60)

1.18 (0.74, 1.50)

(n = 20)

0.84 (0.60, 4.46)

(n = 18)

Baseline body tempreture (℃)

37.5 ± 1.07

37.3 ± 1.90

37.5 ± 1.10

pulse

74.8 ± 11.1

75.8 ± 11.8

72.4 ± 11.4

Hs-CRP (mmol/L)

4.65 (1.80, 13.28)

6.95 (1.73, 18.08)

5.70 (1.80, 17.28)

Ctnl (pg/mL)

0.56 (0.03, 31.2)

0.20 (0.03, 39.1)

14.6 (0.07, 45.4)

CK (U/L)

469.3 (156.8, 952.2)

685.9 (167.5, 1246.3)

526.4 (276.1, 1208.0)

CK-MB (U/L)

30.5 (20.1, 44.8)

41.4 (24.8, 59.5)^*

40.3(25, 54.2)^*

HBDH (U/L)

378.6 (264.9, 506.2)

553.9 (337.5, 707.7)^**

410.2 (300.2, 703.9)

LDH (U/L)

551.7 (355.9, 748.0)

844.2 (478.5, 1225.1)^**

560.0 (401.1, 1039.7)